Nivolumab/Encorafenib/Cetuximab Triplet Elicits High Response Rate in MSS, BRAF V600E-Mutant mCRC
January 22nd 2022The addition of nivolumab to encorafenib and cetuximab elicited a high response rate and an acceptable safety profile in patients with refractory microsatellite stable, BRAF V600E–mutant metastatic colorectal cancer, according to findings from a phase 1/2 trial.
Read More
Daratumumab Plus VTd Enhances MRD-Negativity Rates in Transplant-Eligible Myeloma
December 11th 2021Minimal residual disease–negativity rates were significantly higher after utilizing daratumumab plus bortezomib, thalidomide, and dexamethasone (VTd) vs VTd alone in patients with newly diagnosed, transplant-eligible multiple myeloma, according to findings from the phase 3 CASSIOPEIA study that were presented at the 2021 ASH Annual Meeting and Exposition.
Read More
First-line treatment with ribociclib/letrozole improved overall survival over placebo in patients with postmenopausal, hormone receptor–positive, HER2-negative advanced breast cancer, irrespective of metastatic site, number of sites, or prior (neo)adjuvant chemotherapy and endocrine therapy.
Read More
Melflufen/Dexamethasone Improves PFS in Transplant-Naïve Relapsed/Refractory Multiple Myeloma
September 12th 2021Melphalan flufenamide (melflufen) plus dexamethasone demonstrated an improvement in progression-free survival vs pomalidomide/dexamethasone in patients with transplant-naïve relapsed/refractory multiple myeloma.
Read More
Lenvatinib/Pembrolizumab Yields Survival Benefit in Advanced RCC Across IMDC Risk Groups
June 9th 2021The addition of lenvatinib to pembrolizumab elicited a notable survival benefit and improved responses over single-agent sunitinib in patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups.
Read More
First-Line Ibrutinib Yields 7-Year Survival Benefit in CLL
June 5th 2021Single-agent ibrutinib given in the first-line setting sustained a progression-free survival and overall survival benefit compared with chlorambucil as therapy for patients with chronic lymphocytic leukemia at 7-year follow-up.
Read More
Neoadjuvant Nivolumab/Chemo Improves pCR in Resectable NSCLC
April 10th 2021Neoadjuvant treatment with nivolumab combined with chemotherapy led to a significant improvement in pathologic complete response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.
Read More
JSP191 With Low-Dose Irradiation and Fludarabine Shows Promise in MRD+ AML/MDS
February 9th 2021February 9, 2021 - JSP191 in combination with low-dose total body irradiation and fludarabine has demonstrated efficacy and tolerability in older patients with minimal residual disease–positive acute myeloid leukemia and myelodysplastic syndrome who are undergoing nonmyeloablative allogeneic hematopoietic cell transplantation.
Read More
Frontline Pembrolizumab Maintains Survival Benefit Over Chemo in PD-L1+ NSCLC
January 28th 2021January 28, 2021 — Frontline pembrolizumab continued to demonstrate clinically meaningful improvements in overall survival, overall response rate, and time to progression on next-line therapy compared with platinum-based chemotherapy in patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer without sensitizing EGFR or ALK mutations.
Read More
Addition of Pembrolizumab to Chemo Does Not Negatively Impact QoL in Patients With Esophageal Cancer
January 16th 2021January 16, 2021 - Health-related quality of life during an 18-week period proved to be similar over for patients with esophageal cancer treated with either pembrolizumab or placebo added to chemotherapy.
Read More
Daratumumab plus lenalidomide, bortezomib, and dexamethasone followed by daratumumab and lenalidomide maintenance showed a statistically significant improvement in response rates and depth of responses when compared to RVd followed by lenalidomide maintenance for patients with transplant-eligible newly diagnosed multiple myeloma.
Read More
Mirvetuximab Soravtansine Combination Shows Positive Response, Tolerability in Ovarian Cancer
May 30th 2020Mirvetuximab soravtansine in combination with bevacizumab to treat patients with platinum-agnostic ovarian cancer demonstrated encouraging overall response rates regardless of platinum status with a favorable tolerability profile.
Read More
Cediranib/Olaparib Combo Yields Comparable Results to Chemo in Ovarian Cancer Treatment
May 29th 2020A phase III study using cediranib and olaparib to treat recurrent platinum-sensitive ovarian cancer did not meet its primary endpoint of progression-free survival but did produce comparable activity to standard of care platinum-based chemotherapy treatment.
Read More